Longevity & Aging · Supplements
coffee decreases all-cause mortality
In plain terms: Do coffee drinkers live longer?
Part of: • Coffee
On average, moderate coffee drinkers (about 3-4 cups a day) have a modestly lower risk of dying over time than non-drinkers. It's an association, not proof, and piling on many extra cups doesn't add benefit - but a few cups a day looks, if anything, protective rather than harmful.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
Across very large umbrella reviews and dose-response meta-analyses, moderate coffee drinking (about 3–4 cups/day) is associated with the lowest risk of dying from any cause over follow-up — roughly 13–17% lower than non-drinkers, with the curve flattening or reversing at very high intakes. Caffeinated and decaf both track with the benefit.
The evidence (21)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Shi C et al 2025 · study_type: observational | observational | supports | moderate | UK Biobank prospective cohort using compositional data analysis of coffee/tea/water intake; balanced coffee:tea ratio (~2:3) associated with lowest all-cause mortality HR 0.55 (95% CI 0.47-0.64) vs other combinations. |
| Wang X et al. 2025 · Eur Heart J | observational | supports | moderate | NHANES: morning coffee-drinking pattern HR 0.84 all-cause mortality vs non-drinkers. |
| Yan G et al 2025 · study_type: observational | observational | supports | moderate | NHANES 2001-2018 cohort, 43,114 adults, 6234 deaths over 8.7y median follow-up; coffee drinkers gained up to 2.02 years of life expectancy at age 50 vs non-drinkers (peak at ~2-3 cups/day), driven largely by reduced CVD mortality. |
| Kwapien E et al 2025 · study_type: observational | observational | supports | low | Narrative review (not systematic/meta-analysis) synthesizing cohort literature; concludes moderate coffee intake (3-4 cups/day, ~450-600mL) correlates with reduced all-cause and cardiovascular mortality in a J-shaped dose-response. |
| Li Q et al. 2019 · Nutrients | meta-analysis | supports | high | Dose-response meta 21 cohorts (10M): 3 cups/d RR 0.87; caffeinated approx decaf. |
| Shahinfar H et al. 2021 · Clin Nutr | meta-analysis | supports | moderate | Meta in T2D patients: 4 cups/d HR 0.79 all-cause mortality. |
| Kim Y et al. 2019 · Eur J Epidemiol | meta-analysis | supports | high | Dose-response meta 40 studies (3.85M): nonlinear, nadir 3.5 cups/d RR 0.85. |
| Crippa A et al. 2014 · Am J Epidemiol | meta-analysis | supports | high | Dose-response meta 21 studies: 4 cups/d gives 16% lower all-cause mortality. |
| Liu P et al 2026 · study_type: observational | observational | supports | moderate | NHANES cohort, 21,553 adults with cardiovascular-kidney-metabolic syndrome, 3565 all-cause deaths over 9.2y median follow-up; morning-type coffee pattern HR 0.79 (95% CI 0.65-0.97) for all-cause mortality vs. non-morning/other patterns, wit |
| Yang D et al 2025 · study_type: observational | observational | supports | moderate | NHANES cohort of 5979 adults with prediabetes, 748 deaths; highest vs lowest total coffee consumption HR 0.68 (95% CI 0.55-0.85) for all-cause mortality; benefit seen across sugar-sweetened, sugar-free, full-fat, and fat-free coffee subtype |
| Chen QY et al 2025 · study_type: meta-analysis | meta-analysis | supports | moderate | Meta-analysis (DerSimonian-Laird random effects) of postdiagnosis dietary/lifestyle factors in colorectal cancer patients; coffee intake associated with lower all-cause mortality, summary RR 0.65 (95% CI 0.55-0.77). |
| Poole R et al. 2017 · BMJ | meta-analysis | supports | high | Umbrella (201 meta-analyses): 3-4 cups/d largest reduction, all-cause mortality RR 0.83. |
| Schaefer SM et al. 2022 · Clin Nutr | observational | mixed | high | UK Biobank (354k): weak/possible inverse; nadir ~2 cups/d, effect modest. |
| Emadi RC et al 2025 · study_type: observational | observational | supports | low | Narrative review of coffee's health effects citing 'numerous large-scale prospective cohorts' showing moderate intake (3-5 cups/day) is consistently associated with reduced overall mortality; notes benefit for both caffeinated and decaf. |
| Zhao Y et al. 2015 · Public Health Nutr | meta-analysis | supports | moderate | Meta 17 studies (1.05M): 3 to <5 cups/d RR 0.87; stronger in women. |
| Watanabe D et al 2025 · study_type: observational | observational | supports | moderate | Kyoto-Kameoka prospective cohort of 7708 Japanese adults ≥65y, 593 deaths over 4.75y median follow-up; ≥3 cups/day coffee vs non-consumption HR 0.62 (95% CI 0.43-0.88) for all-cause mortality; caffeine itself was not significantly associate |
| Shin S et al. 2022 · Int J Epidemiol | observational | supports | high | Asia Cohort Consortium (528k): >=5 cups/d 24% (men)/28% (women) lower all-cause mortality. |
| Grosso G et al. 2017 · Annu Rev Nutr | meta-analysis | supports | high | Umbrella: coffee rated probable decreased risk of CVD and all-cause mortality. |
| Loftfield E et al. 2018 · JAMA Intern Med | observational | supports | high | UK Biobank (498k): HR 0.84-0.94 across intake incl >=8 cups/d; no CYP1A2 genotype modification. |
| Ribeiro EM et al. 2020 · Clin Nutr ESPEN | meta-analysis | mixed | moderate | Meta post-MI: all-cause mortality HR 0.85 (ns); CV mortality HR 0.70. |
| Grosso G et al. 2016 · Am J Epidemiol | meta-analysis | supports | high | Dose-response meta 31 studies (1.6M): RR 0.86 up to 4 cups/d; linear inverse in non-smokers. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.